News & Updates

Download this free white paper to unlock expert insights and strategic guidance designed to help biopharma partners navigate the rapidly evolving ADC therapeutic landscape.

Sweeping federal policy changes and demonstrations (IRA, MFN, DTP, O3BA) are set to increase the cost burden US patients will soon face for specialty and biologic therapies. In addition to policy changes, health plan designs (e.g., copay adjustment programs) as well as unexpected pharmacy practices (e.g., improper claims) may negatively impact biopharmaceutical brands’ gross to net (GTN) performance and patient support programs.

In this session, you will learn how to strengthen your patient support program design to better meet patient needs, all while protecting gross-to-net. We’ll discuss:

• The expected impact of federal policy changes and demonstrations on GTN performance for specialty and biologic therapies
• Strategies to identify and address unprofitable claims
• Approaches to better determine patient needs at the time of enrollment
• AI-driven methods for monitoring and improving pharmacy practices 

A four-part live analyst series exploring the biggest trends shaping 2026, from obesity blockbusters to rare disease innovation, oncology breakthroughs and women's health.

The path to AI success in healthcare analytics is fraught with hidden costs and market risks. This essential comparison guide breaks down the strategic risks of these common AI adoption models and reveals the third way: a unified approach built specifically for the complexities of healthcare.

Download this free Insights™ report to see how AI is transforming life sciences by turning fragmented data into faster decisions, accelerated discovery, and stronger R&D ROI.

Healthcare commercialization is shifting from fragmented services to integrated patient ecosystems. This white paper examines why end-to-end models, advanced technology, and strategic partnerships are redefining access, efficiency, and value creation. Download the white paper to learn more.

Autoimmune diseases are dynamic, varied, and difficult to characterize using traditional clinical visits and static datasets. As drug developers rely on AI and biomarker-driven approaches to understand disease activity and therapeutic response, they face a fundamental limitation: most available data offers only isolated snapshots in time, missing the dynamic transitions that truly define immune-mediated conditions.                              

In this discussion, our speakers will explore how longitudinal, temporally relevant, multimodal data collected through direct connections with individuals can help unlock new opportunities across early R&D for immune-mediated diseases. Attendees will gain insights on how these data can be used to sharpen R&D confidence in early-phase programs and support AI-driven innovation in autoimmune drug development.

• Learn how to redesign your autoimmune data strategy by identifying gaps in current data sets and determining where continuous data collection can strengthen biomarkers and translational efforts
• Apply real world and molecular signals to detect early flare signatures and characterize transitions between disease states
• Integrate longitudinal evidence into biomarker development decisions
• Strengthen translational and early development strategy with time-based patterns in immune activity data     

When your molecule is ready for the next stage, you need more than a service provider, you need a partner who guarantees a seamless, compliant, and transparent technology transfer. Find out more from Dante Lepore, Laboratory Head of Downstream Process Development at Rentschler Biopharma. 

As global uncertainty grows, biotech and biopharma companies are rethinking manufacturing strategies to reduce risk and ensure continuity. Onshoring drug substance development for biologics offers a powerful way to strengthen control, improve reliability, and accelerate timelines. This webinar will explore the strategic advantages of onshoring, including streamlined regulatory compliance, improved process oversight, and greater flexibility for innovation. Industry experts will share practical insights on planning and executing onshore transitions, technology considerations, and how these efforts can safeguard critical programs. Join us to learn why onshoring is becoming a cornerstone of risk mitigation and long-term success in biologics manufacturing.